Ticker brief
NWBO NORTHWEST BIOTHERAPEUTICS
Consumer, Non-cyclical · Pharmaceuticals
last close
$0.1896
1 day
+5.8%
14 days
-1.3%
mkt cap
$312.2M
signals 14d
32
authors 14d
4
crowd 14d
-0.0σ
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now +0.08 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PK_Fund | C | +0.11 | 13 | +0.55 |
| @YYDSxjm | B | -0.51 | 9 | +0.43 |
| @AponiaAnalytics | B | +4.91 | 7 | +0.09 |
| @ChrisLaCoursie1 | C | +0.10 | 3 | +0.52 |
Recent signals30of 32 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @AponiaAnalytics | +0.05 | Reviews multi-part immunotherapy strategies for glioblastoma while stressing absent survival proof. | — | tweet ↗ |
| 2026-08-28 | @AponiaAnalytics | +0.10 | Discusses coordinated immune activation and tumor-microenvironment remodeling in glioblastoma. | — | tweet ↗ |
| 2026-08-27 | @ChrisLaCoursie1 | +0.45 | Promotes a 4 p.m. event as an exceptional opportunity for the listed stocks. | +5.8% | tweet ↗ |
| 2026-08-27 | @YYDSxjm | +0.45 | Argues Saudi buying could raise volume, squeeze shorts, and support uplisting. | +5.8% | tweet ↗ |
| 2026-08-27 | @PK_Fund | +0.45 | Hopes an upcoming CHM meeting will become a positive catalyst for NWBO. | +5.8% | tweet ↗ |
| 2026-08-26 | @AponiaAnalytics | +0.05 | Summarizes preclinical prostate-cancer macrophage research while emphasizing absent clinical efficacy | +9.6% | tweet ↗ |
| 2026-08-26 | @AponiaAnalytics | +0.05 | Summarizes a mouse study of cDC2-targeted allergen tolerance and highlights translational limitations | +9.6% | tweet ↗ |
| 2026-08-26 | @AponiaAnalytics | +0.15 | Reviews dendritic-cell dysfunction as an upstream immunotherapy-resistance mechanism | +9.6% | tweet ↗ |
| 2026-08-26 | @AponiaAnalytics | +0.10 | Reviews dendritic-cell vaccine limitations and possible improvements to subtype and trafficking | +9.6% | tweet ↗ |
| 2026-08-26 | @AponiaAnalytics | +0.10 | Reports durable murine glioblastoma nanovaccine results while stressing weak clinical applicability | +9.6% | tweet ↗ |
| 2026-08-26 | @PK_Fund | +0.85 | Added shares past 500,000 total and expects regulatory approval. — Reports crossing 500,000 shares through additional buying and explicitly expects approval. | +9.6% | tweet ↗ |
| 2026-08-26 | @YYDSxjm | -0.20 | Frustrated holder says minor flows are meaningless and the stock needs substantive news. | +9.6% | tweet ↗ |
| 2026-08-25 | @PK_Fund | -0.10 | Questions how close NWBO truly is to a milestone despite 'one-yard-line' claims. | +9.0% | tweet ↗ |
| 2026-08-25 | @YYDSxjm | -0.45 | Claims heavy buying volume was overwhelmed by smaller closing sell volume due to manipulation. | +9.0% | tweet ↗ |
| 2026-08-24 | @PK_Fund | +0.50 | Highlights litigation discovery, an MHRA decision and Saudi developments as converging catalysts. | +9.9% | tweet ↗ |
| 2026-08-24 | @PK_Fund | +0.70 | Dismisses Moderna results as a hit piece and anticipates NWBO approval. | +9.9% | tweet ↗ |
| 2026-08-21 | @YYDSxjm | +0.75 | Uses Moderna's Phase 3-driven valuation surge to argue NWBO may have greater potential. | +11.8% | tweet ↗ |
| 2026-08-21 | @YYDSxjm | +0.60 | Frames NWBO's short-term pain as a precursor to long-term gains. | +11.8% | tweet ↗ |
| 2026-08-21 | @PK_Fund | +0.30 | Reports a WHO ATC objection deadline and potential progression toward final 2027 classification. | +11.8% | tweet ↗ |
| 2026-08-20 | @ChrisLaCoursie1 | +0.90 | Claims NWBO offers 50x upside without trade mechanics. | +10.7% | tweet ↗ |
| 2026-08-19 | @PK_Fund | +0.95 | Strongly endorses DCVax-L's breadth and explicitly says to hold NWBO. | +6.8% | tweet ↗ |
| 2026-08-19 | @YYDSxjm | +0.90 | Author strongly endorses NWBO's science and urges holders to remain patient. | +6.8% | tweet ↗ |
| 2026-08-19 | @YYDSxjm | +0.90 | Author predicts a sharp NWBO launch and warns short sellers. | +6.8% | tweet ↗ |
| 2026-08-19 | @PK_Fund | +0.80 | Argues NWBO deserves a valuation reassessment based on manufacturing speed and treatment pricing. | +6.8% | tweet ↗ |
| 2026-08-19 | @ChrisLaCoursie1 | +0.20 | Take a speculative flyer, especially ahead of an expected NTRP move — Invites a speculative long aimed at defeating shorts and predicts NTRP upside. | +6.8% | tweet ↗ |
| 2026-08-19 | @PK_Fund | +0.25 | Author outlines discovery questions in NWBO litigation using the JPM spoofing case as precedent. | +6.8% | tweet ↗ |
| 2026-08-19 | @YYDSxjm | +0.50 | Expects settlements after a judge's prior ruling and sees no new reason for reversal. | +6.8% | tweet ↗ |
| 2026-08-19 | @PK_Fund | +0.65 | Author praises NWBO's team and argues defendants should face contempt. | +6.8% | tweet ↗ |
| 2026-08-18 | @PK_Fund | +0.75 | Added 9,000 NWBO shares and remains long 180,000 shares. — Explicitly discloses adding 9,000 NWBO shares to reach a 180,000-share position. | +5.4% | tweet ↗ |
| 2026-08-16 | @PK_Fund | +0.65 | Argues compelled algorithm discovery could expose manipulation and trigger a short squeeze. | -1.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.